Literature DB >> 20934192

NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events.

Joseph D Weissman1, German A Khunteev, Roslyn Heath, Svetlana A Dambinova.   

Abstract

BACKGROUND AND
PURPOSE: Predicting stroke using biomarkers would enable clinicians to help prevent stroke or mitigate damage. Several stroke biomarkers have been investigated but none has shown near term predictive value.
METHODS: We studied patients presenting with a history of stroke or transient ischemic attack (TIA) to determine whether serum levels of autoantibodies to the NMDA receptor NR2 peptide (NR2Ab) reflected the presence of recent stroke compared with controls. Antibody levels were also correlated with clinical risk factors for stroke, including diabetes, hypertension, hyperlipidemia, and history of recent TIA or stroke.
RESULTS: Of the 245 patients that presented with acute stroke or TIA, 130 consented to participate and results are available for the 120. Volunteers from the community were recruited as controls. Males and females with multiple recent strokes and females with acute strokes had elevated NR2Ab levels compared to non-stroke patients or controls. Using a multiple regression model, the predictive value for NR2Ab was compared to clinical risk factors. In men, the presence of stroke correlated with hypertension (p<0.001) and NR2Ab levels (p<0.01) and in women the presence of stroke correlated with hypertension (p<0.001), diabetes (p<0.05), atrial fibrillation (p<0.05) and NR2Ab (p<0.01).
CONCLUSION: These results suggest that NR2Ab levels reflect a history of multiple strokes and may serve as a predictive factor for stroke.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20934192     DOI: 10.1016/j.jns.2010.09.023

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  23 in total

1.  Candidate Biomarkers for the Diagnosis of Transient Ischemic Attack: A Systematic Review.

Authors:  L Servaas Dolmans; Frans H Rutten; Niels C T Koenen; Marie-Louise E L Bartelink; Johannes B Reitsma; L Jaap Kappelle; Arno W Hoes
Journal:  Cerebrovasc Dis       Date:  2019-08-30       Impact factor: 2.762

2.  Stroke induces a rapid adaptive autoimmune response to novel neuronal antigens.

Authors:  Sterling B Ortega; Ibrahim Noorbhai; Katie Poinsatte; Xiangmei Kong; Ashley Anderson; Nancy L Monson; Ann M Stowe
Journal:  Discov Med       Date:  2015-05       Impact factor: 2.970

3.  High-throughput profiling of the circulating proteome suggests sexually dimorphic corticosteroid signaling following ischemic stroke.

Authors:  Grant C O'Connell; Kyle B Walsh; Emily Burrage; Opeolu Adeoye; Paul D Chantler; Taura L Barr
Journal:  Physiol Genomics       Date:  2018-07-20       Impact factor: 3.107

Review 4.  Does B lymphocyte-mediated autoimmunity contribute to post-stroke dementia?

Authors:  Kristian P Doyle; Marion S Buckwalter
Journal:  Brain Behav Immun       Date:  2016-08-13       Impact factor: 7.217

Review 5.  Biomarkers for childhood-onset systemic lupus erythematosus.

Authors:  Khalid M Abulaban; Hermine I Brunner
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 6.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

7.  Stroke patients develop antibodies that react with components of N-methyl-D-aspartate receptor subunit 1 in proportion to lesion size.

Authors:  Maggie L Kalev-Zylinska; Wymond Symes; Kevin C E Little; Peng Sun; Daying Wen; Linzi Qiao; Deborah Young; Matthew J During; P Alan Barber
Journal:  Stroke       Date:  2013-05-30       Impact factor: 7.914

Review 8.  Infection as a Stroke Risk Factor and Determinant of Outcome After Stroke.

Authors:  Mitchell S V Elkind; Amelia K Boehme; Craig J Smith; Andreas Meisel; Marion S Buckwalter
Journal:  Stroke       Date:  2020-09-08       Impact factor: 7.914

Review 9.  Antigen Presentation After Stroke.

Authors:  Francesc Miró-Mur; Xabier Urra; Mattia Gallizioli; Angel Chamorro; Anna M Planas
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

10.  Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke.

Authors:  Svetlana A Dambinova; Kerstin Bettermann; Theodore Glynn; Matthew Tews; David Olson; Joseph D Weissman; Richard L Sowell
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.